Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total value of $56,576.60. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at $3,693,565.40. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Down 0.8%

Shares of NYSE EW opened at $90.47 on Wednesday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a market cap of $52.09 billion, a price-to-earnings ratio of 48.12, a PEG ratio of 2.29 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $92.88. The stock has a 50-day moving average price of $84.85 and a two-hundred day moving average price of $83.36.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the company posted $0.64 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Barclays restated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. TD Cowen reissued a “buy” rating and set a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $96.39.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the 1st quarter worth $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $27,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.